Cisplatin-induced ototoxicity in humans is more predominant in the cochlea than in the
vestibule. Neither definite nor substantial vestibular dysfunction after cisplatin treatment has …

Significance: Cisplatin is an important component of treatment regimens for different
cancers. Notwithstanding that therapeutic success often results from partial efficacy or …

Background Excessive accumulation of reactive oxygen species (ROS) has been
documented as the crucial cellular mechanism of cisplatin-induced ototoxicity. However …

Accumulating evidence suggests that cochlear deafferentation may contribute to
suprathreshold deficits observed with or without elevated hearing thresholds, and can lead …

Permanent hearing loss is one of cisplatin's adverse effects, affecting 30–60% of cancer
patients treated with that drug. Our research group recently identified resident mast cells in …

The sound-evoked electrical compound potential known as auditory brainstem response
(ABR) represents the firing of a heterogenous population of auditory neurons in response to …

Altered expression of peripheral myelin protein 22 (PMP22) results in demyelinating
peripheral neuropathy. PMP22 exhibits a highly restricted tissue distribution with marked …

Antioxidant 1 copper chaperone (Atox1) may contribute to preventing DDP cochlear damage
by regulating copper transport family and cell cycle proteins. A rat model of cochlear …

Hearing loss is the most common form of sensory deficit. It occurs predominantly due to hair
cell (HC) loss. Mammalian HCs are terminally differentiated by birth, making HC loss …

Abstract Treatment in oncology may lead to several adverse side effects, including those
affecting the nervous system. These side effects may reduce the quality of life of patients …